$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022002392 Filed on March 01, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q3
Revenue	$115.5M	$130.8M	$131.6M
YoY Change	8.37%	8.06%	9.15%
Cost Of Revenue	$2.950M	$2.561M	$6.682M
YoY Change	35.01%	-51.68%	39.21%
Gross Profit	$112.5M	$128.3M	$127.9M
YoY Change	7.81%	8.28%	7.89%
Gross Profit Margin	97.45%	98.13%	97.2%
Selling, General & Admin	$96.68M	$105.9M	$81.67M
YoY Change	-13.42%	-12.32%	0.08%
% of Gross Profit	85.92%	82.54%	63.84%
Research & Development	$128.9M	$66.94M	$58.57M
YoY Change	126.17%	7.8%	-51.24%
% of Gross Profit	114.52%	52.17%	45.78%
Depreciation & Amortization	$516.0K	$535.0K	$985.0K
YoY Change	-1.71%	-36.31%	38.73%
% of Gross Profit	0.46%	0.42%	0.77%
Operating Expenses	$225.5M	$172.9M	$140.2M
YoY Change	33.74%	-5.49%	-30.48%
Operating Profit	-$113.0M	-$44.54M	-$12.31M
YoY Change	69.26%	-30.84%	-85.2%
Interest Expense	$105.0K	$129.0K	$129.0K
YoY Change	-47.5%	-78.5%	-89.25%
% of Operating Profit
Other Income/Expense, Net	$340.0K	$1.623M	$383.0K
YoY Change	-334.48%	441.0%	-291.5%
Pretax Income	-$112.6M	-$42.91M	-$14.79M
YoY Change	69.47%	-35.29%	-82.58%
Income Tax	$485.0K	$189.0K	-$332.0K
% Of Pretax Income
Net Earnings	-$113.1M	-$43.09M	-$14.46M
YoY Change	70.14%	-35.45%	-82.92%
Net Earnings / Revenue	-97.91%	-32.96%	-10.98%
Basic Earnings Per Share	-$0.70	-$0.27	-$0.09
Diluted Earnings Per Share	-$701.2K	-$264.3K	-$89.98K
COMMON SHARES
Basic Shares Outstanding	161.2M		160.7K
Diluted Shares Outstanding	161.2M		160.7K

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$446.0M	$520.7M	$540.3M
YoY Change	-22.81%	-17.6%	-16.16%
Cash & Equivalents	$204.9M	$147.4M	$100.4M
Short-Term Investments	$241.1M	$373.3M	$445.7M
Other Short-Term Assets	$25.76M	$23.89M	$24.62M
YoY Change	-9.63%	-7.04%	-17.93%
Inventory	$13.21M	$14.10M	$14.34M
Prepaid Expenses	$25.76M	$23.89M
Receivables	$62.71M	$64.37M	$60.70M
Other Receivables	$769.0K	$978.0K	$972.0K
Total Short-Term Assets	$542.2M	$617.8M	$640.9M
YoY Change	-19.55%	-13.91%	-12.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.531M	$8.047M	$68.61M
YoY Change	-89.67%	-12.16%	21.01%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets	$4.336M	$3.997M	$2.373M
YoY Change	-42.95%	138.2%	-67.49%
Total Long-Term Assets	$82.03M	$82.30M	$76.76M
YoY Change	1.02%	26.61%	17.18%
TOTAL ASSETS
Total Short-Term Assets	$542.2M	$617.8M	$640.9M
Total Long-Term Assets	$82.03M	$82.30M	$76.76M
Total Assets	$624.3M	$700.1M	$717.7M
YoY Change	-17.34%	-10.54%	-9.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.77M	$6.876M	$7.722M
YoY Change	22.36%	-19.04%	120.63%
Accrued Expenses	$108.8M	$89.19M	$80.50M
YoY Change	8.27%	-8.5%	-8.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$119.6M	$96.07M	$88.22M
YoY Change	9.33%	-9.34%	-4.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.373M	$7.034M	$62.50M
YoY Change	-93.19%	35.79%	27.81%
Total Long-Term Liabilities	$4.373M	$7.034M	$62.50M
YoY Change	-93.19%	35.79%	27.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$119.6M	$96.07M	$88.22M
Total Long-Term Liabilities	$4.373M	$7.034M	$62.50M
Total Liabilities	$179.5M	$159.2M	$150.7M
YoY Change	3.37%	2.33%	7.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.267B	-$2.154B
YoY Change		8.45%
Common Stock	$2.712B	$2.695B
YoY Change		3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$444.8M	$540.9M	$567.0M
YoY Change
Total Liabilities & Shareholders Equity	$624.3M	$700.1M	$717.7M
YoY Change	-17.34%	-10.54%	-9.81%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$113.1M	-$43.09M	-$14.46M
YoY Change	70.14%	-35.45%	-82.92%
Depreciation, Depletion And Amortization	$516.0K	$535.0K	$985.0K
YoY Change	-1.71%	-36.31%	38.73%
Cash From Operating Activities	-$76.33M	-$23.12M	-$17.06M
YoY Change	26.9%	-15.9%	-25.13%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$1.000K	$0.00
YoY Change	-100.0%	-99.95%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$131.3M	$71.55M	-$156.3M
YoY Change	311.1%	-162.24%	-201.03%
Cash From Investing Activities	$131.3M	$71.55M	-$156.3M
YoY Change	325.38%	-161.17%	-202.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.467M
YoY Change	-68.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.467M	4.365M	1.066M
YoY Change	-68.07%	-75.92%	-90.9%
NET CHANGE
Cash From Operating Activities	-76.33M	-23.12M	-17.06M
Cash From Investing Activities	131.3M	71.55M	-156.3M
Cash From Financing Activities	2.467M	4.365M	1.066M
Net Change In Cash	57.49M	52.79M	-172.3M
YoY Change	-366.86%	-141.79%	-221.42%
FREE CASH FLOW
Cash From Operating Activities	-$76.33M	-$23.12M	-$17.06M
Capital Expenditures	$0.00	-$1.000K	$0.00
Free Cash Flow	-$76.33M	-$23.12M	-$17.06M
YoY Change	24.67%	-9.3%	-19.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2019	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
CY2020Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q1	us-gaap	Jointly Owned Utility Plant Proportionate Ownership Share JointlyOwnedUtilityPlantProportionateOwnershipShare	0.50
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	000-50768
CY2021	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1376651
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	12830 El Camino Real
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	558-2871
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	ACAD
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2500000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161203748
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	California
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326028000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	373271000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	305930000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64366000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48247000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	978000
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2035000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2020Q4	acad	Short Term Inventory ShortTermInventory	9682000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23892000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25694000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	617823000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	717616000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9161000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58268000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	47283000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1108000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3997000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1678000
CY2021Q4	us-gaap	Assets Assets	700122000
CY2020Q4	us-gaap	Assets Assets	782616000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6876000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8493000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	97474000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96068000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105967000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44460000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7034000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5180000
CY2021Q4	us-gaap	Liabilities Liabilities	159228000
CY2020Q4	us-gaap	Liabilities Liabilities	155607000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11344000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161012695
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161012695
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	159637771
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	159637771
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2694646000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2612663000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2153576000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1985706000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-192000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	36000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627009000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	700122000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	782616000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	441755000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	339076000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10843000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10211000
CY2021	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	8298000
CY2020	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	10339000
CY2019	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	8254000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	396028000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	388661000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	239415000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	319130000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	240385000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	325638000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	654584000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	728341000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	585621000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-170439000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-286586000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-246545000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	591000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6610000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	11165000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2329000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-997000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	997000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167519000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-280973000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-234383000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	611000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	876000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	160493000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	157331000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	147199000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-235000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-253000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	667000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-168098000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-281845000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-234590000
CY2021	us-gaap	Profit Loss ProfitLoss	-167870000
CY2020	us-gaap	Profit Loss ProfitLoss	-281584000
CY2019	us-gaap	Profit Loss ProfitLoss	-235259000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	63615000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	84422000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	82265000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63821000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-228000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2404000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1470000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3613000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1108000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1477000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1477000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	2329000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-997000
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	997000
CY2021	us-gaap	Depreciation Depreciation	2236000
CY2020	us-gaap	Depreciation Depreciation	1455000
CY2019	us-gaap	Depreciation Depreciation	1289000
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-281000
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	44280000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16119000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12466000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9691000
CY2021	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1057000
CY2020	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-58000
CY2019	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	394000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4210000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3320000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1737000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1802000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7088000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2121000
CY2021	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-6287000
CY2020	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-4280000
CY2019	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-3875000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-182000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-39000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1617000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1271000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4055000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8455000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	27569000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6458000
CY2021	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5433000
CY2020	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1769000
CY2019	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2518000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1854000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2319000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1497000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-125660000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136166000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-151130000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	492797000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	339908000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	578634000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	422817000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	540004000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	413927000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1122000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7587000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1129000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71102000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	192509000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165836000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18162000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80996000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	371847000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18162000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80996000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	371847000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-178593000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137331000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54883000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	139584000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1038000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1113000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1597000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	130000
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	34000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	44280000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	479079000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	271452000
CY2019	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	95984000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4411000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82799000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	669000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	699135000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	44280000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	73834000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7162000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5312000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627009000
CY2021	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	12850000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	84443000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-261000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326028000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189680000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326028000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4787000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1300000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	400000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1100000
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2016Q2	acad	Regulatory Milestone Payment RegulatoryMilestonePayment	8000000.0
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8000000.0
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	41800000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	51100000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	38300000
CY2021Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, investment securities, accounts receivable, and restricted cash. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All investment securities have a credit rating of at least Aa3/AA- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of NUPLAZID for commercial use and for the production of its product candidates for clinical trials. The Company has contracts in place with two third-party manufacturers of commercial drug product and one third-party manufacturer of drug substance that is approved for the production of NUPLAZID active pharmaceutical ingredient (API). Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into distribution agreements with a limited number of SPs and SDs, and all of the Company’s product sales are to these customers. For the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company’s </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s accounts receivable balance at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021. For the year ended December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company’s </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s accounts receivable balance at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020. For the year ended December 31, 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company’s </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s accounts receivable balance at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
CY2021	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2020	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2019	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82265000
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	6800000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63615000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84422000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17535000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19331000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19516000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	169353000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	43000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	169353000
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	43000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	373475000
CY2021Q4	acad	Equity Securities Fv Ni Unrealized Gains EquitySecuritiesFvNiUnrealizedGains	9000
CY2021Q4	acad	Equity Securities Fv Ni Unrealized Losses EquitySecuritiesFvNiUnrealizedLosses	213000
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	373271000
CY2020Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	305899000
CY2020Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	74000
CY2020Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	43000
CY2020Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	305930000
CY2021	acad	Available For Sale Investment Securities Contractual Maturity Dates AvailableForSaleInvestmentSecuritiesContractualMaturityDates	less than one year
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	39
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	24
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	213000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	213000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	499785000
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	632576000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1114000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1453000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6767000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6367000
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6217000
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1862000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2020Q4	us-gaap	Inventory Net InventoryNet	9682000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2020Q4	acad	Short Term Inventory ShortTermInventory	9682000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2020Q4	us-gaap	Inventory Net InventoryNet	9682000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14231000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13109000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6184000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3948000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9161000
CY2021	us-gaap	Depreciation Depreciation	2200000
CY2020	us-gaap	Depreciation Depreciation	1500000
CY2019	us-gaap	Depreciation Depreciation	1300000
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3100000
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	200000
CY2021Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	27270000
CY2020Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	28380000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25896000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25811000
CY2021Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	15717000
CY2020Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	14115000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9319000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	18969000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5087000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2686000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5112000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	97474000
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	271500000
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7187500
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16441994
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.40
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1879092
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	43.62
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	577627
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2657318
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	34.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15086141
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.58
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16416000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	11003784
CY2021Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	30.09
CY2021	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2021Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue1	12879000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4082357
CY2021Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice	35.60
CY2021	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2021Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue1	3537000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000000.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	55500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	56600000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12900
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	73800000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.07
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.97
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	99100000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	PSUs for which the number of shares issuable at the end of performance period can reach up to 200% of the shares approved in the award based on the achievement of certain pre-defined Acadia-specific performance criteria and continued employment through the vesting period
CY2021Q4	us-gaap	Banking Regulation Maximum Payout Amount BankingRegulationMaximumPayoutAmount	15100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4400000
CY2021	us-gaap	Banking Regulation Maximum Payout Amount BankingRegulationMaximumPayoutAmount	14600000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5600000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	600000
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5800000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5100000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	4300000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-138913000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-238885000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-123411000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-28606000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-42088000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-110972000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-167519000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-280973000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-234383000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	400000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	400000
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	900000
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	200000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	100000
CY2021Q4	acad	Federal Research And Development Credit Carryforwards FederalResearchAndDevelopmentCreditCarryforwards	65800000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	229476000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	218905000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	74702000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	63886000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51170000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	47547000
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	41355000
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	28470000
CY2021Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	15550000
CY2020Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	11675000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6741000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7109000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6073000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11700000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9390000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	430694000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	393055000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416630000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	380533000
CY2021Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	14063000
CY2020Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	11142000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1380000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14064000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12522000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36100000
CY2019Q4	acad	Deferred Tax Asset Switzerland Tax Reform DeferredTaxAssetSwitzerlandTaxReform	57000000.0
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-35179000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59004000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-49365000
CY2021	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	6696000
CY2020	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	991000
CY2019	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	5691000
CY2021	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	1277000
CY2020	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	9565000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-11727000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-17909000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-16687000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36099000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5925000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	99846000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2617000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5038000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2138000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	3879000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2665000
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1861000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2857000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4208000
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	20413000
CY2021	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	1808000
CY2020	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	3705000
CY2019	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	1178000
CY2021	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	-2424000
CY2020	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	2130000
CY2021	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-923000
CY2020	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	53045000
CY2019	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-59181000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	605000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	328000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-742000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	611000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	876000
CY2021	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	4100000
CY2020	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	2900000
CY2019	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	1900000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2020	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2019	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9843000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6945000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5037000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3973000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2722000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1908000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	140000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	212000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	33000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	36000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13923000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9843000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6945000
CY2021	acad	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2031-02
CY2021	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 2.0 year to 9.4 years, some of which include options to extend the lease for up to two five-year terms.
CY2021	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	some of which include options to extend the lease for up to two five-year terms.
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8874000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	6917000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	5155000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5303000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	4480000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17272000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	42039000
CY2021	us-gaap	Revenues Revenues	484145000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5087000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44460000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64430000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	49547000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8520000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8390000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8275000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8355000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7719000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	36556000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	77815000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13385000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64430000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.043
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.047
CY2020Q3	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	40300000
CY2021Q1	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	19200000
CY2021Q1	us-gaap	Revenues Revenues	106554000
CY2021Q2	us-gaap	Revenues Revenues	115221000
CY2021Q3	us-gaap	Revenues Revenues	131612000
CY2021Q4	us-gaap	Revenues Revenues	130758000
CY2021Q1	us-gaap	Gross Profit GrossProfit	104369000
CY2021Q2	us-gaap	Gross Profit GrossProfit	112695000
CY2021Q3	us-gaap	Gross Profit GrossProfit	127924000
CY2021Q4	us-gaap	Gross Profit GrossProfit	128314000
CY2021	us-gaap	Gross Profit GrossProfit	473302000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-66448000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-43871000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14457000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-43094000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2021Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2020Q1	us-gaap	Revenues Revenues	90068000
CY2020Q2	us-gaap	Revenues Revenues	110103000
CY2020Q3	us-gaap	Revenues Revenues	120577000
CY2020Q4	us-gaap	Revenues Revenues	121007000
CY2020	us-gaap	Revenues Revenues	441755000
CY2020Q1	us-gaap	Gross Profit GrossProfit	87269000
CY2020Q2	us-gaap	Gross Profit GrossProfit	107204000
CY2020Q3	us-gaap	Gross Profit GrossProfit	118572000
CY2020Q4	us-gaap	Gross Profit GrossProfit	118499000
CY2020	us-gaap	Gross Profit GrossProfit	431544000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88023000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-42141000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-84660000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-66760000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79

Files In Submission

Name	View Source	Status
0000950170-22-002392-index-headers.html	Edgar Link	pending
0000950170-22-002392-index.html	Edgar Link	pending
0000950170-22-002392.txt	Edgar Link	pending
0000950170-22-002392-xbrl.zip	Edgar Link	pending
acad-20211231.htm	Edgar Link	pending
acad-20211231.xsd	Edgar Link	pending
acad-20211231_cal.xml	Edgar Link	unprocessable
acad-20211231_def.xml	Edgar Link	unprocessable
acad-20211231_htm.xml	Edgar Link	completed
acad-20211231_lab.xml	Edgar Link	unprocessable
acad-20211231_pre.xml	Edgar Link	unprocessable
acad-ex10_11.htm	Edgar Link	pending
acad-ex10_9.htm	Edgar Link	pending
acad-ex21_1.htm	Edgar Link	pending
acad-ex23_1.htm	Edgar Link	pending
acad-ex31_1.htm	Edgar Link	pending
acad-ex31_2.htm	Edgar Link	pending
acad-ex32_1.htm	Edgar Link	pending
acad-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img234459076_0.jpg	Edgar Link	pending
img234459076_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2022 Q1 Form 10-K Financial Statement

#000095017022002392 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2022 Q1 Form 10-K Financial Statement

#000095017022002392 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad